#None #CEO #Suanfarma #Pere Mañé

Pere Mañé Takes Over as Suanfarma’s New CEO

In a bold move that signals a new phase for Suanfarma, globally recognized for its excellence in active pharmaceutical ingredients (APIs) and contract development and manufacturing organization (CDMO) services, Pere Mañé Godina has been appointed as the new Chief Executive Officer (CEO). This appointment, announced on April 22, 2025, comes at a crucial time for the company, which is looking to strengthen its market position and enhance its operational capabilities for the health industry.

A New Era for Suanfarma

With a rich professional background that spans over three decades, Pere Mañé brings a wealth of experience from some of the foremost companies in the pharmaceutical sector, including Uquifa and Boehringer Ingelheim. His most recent role involved significant contributions to the industrial transformation of Esteve, where he adeptly repositioned the chemical division, earning crucial accolades such as CDMO of the Year – Small Molecules at the prestigious DCAT 2025 Leadership Awards.

“Pere’s expertise is exactly what Suanfarma needs as we embark on this crucial phase of growth,” stated the interim CEO Carlos Alonso, who will continue with the company as Executive Chairman to ensure a seamless transition. The board is optimistic that Pere’s strategic mindset and deep understanding of the pharmaceutical landscape will be instrumental in advancing Suanfarma’s objectives.

Focusing on Growth and Innovation

Under his leadership, Suanfarma aims to achieve multiple objectives: streamlining operations, integrating cutting-edge technologies, and significantly enhancing relationships with global clients and suppliers. Moreover, Pere emphasizes a critical focus on accelerating international expansion and fostering a strong culture of sustainability and innovation to drive the company forward.

Pere commented, “Suanfarma possesses the foundational elements needed to lead the future of the industry, including a robust infrastructure, an exceptional team, and a valuable international network. I am looking forward to this new journey together and committed to delivering innovative and sustainable solutions to our clients.”

The Strategic Vision Ahead

Pere’s strategy revolves around several key initiatives:

• - Streamlining Operations: By refining workflow processes and reducing inefficiencies, Pere plans to enhance productivity across all levels of operation.
• - Embracing Technology: He advocates for the adoption of advanced technological solutions to improve product quality and production effectiveness.
• - Strengthening Supply Chains: By nurturing robust relationships with suppliers globally, Pere seeks to fortify Suanfarma’s supply chain resilience.
• - Pursuing Global Opportunities: There is a dynamic focus on penetrating new markets and enhancing international collaborations to leverage growth potential.
• - Championing Sustainability: Pere’s commitment to innovation is closely tied to sustainable practices, ensuring that Suanfarma not only grows but does so responsibly in alignment with global health challenges.

About Suanfarma

Founded in 1993, Suanfarma has established itself as a reliable B2B partner in the life sciences sector, dedicated to health and wellness through sustainable practices in the development and production of high-quality pharmaceutical ingredients. With a presence in more than 70 countries and support from the healthcare-focused investment firm Archimed since 2021, Suanfarma is well-positioned for a future of innovation and growth.

As Pere Mañé steps into his new role, all eyes are on Suanfarma, anticipating significant advancements in pharmaceutical manufacturing and a strong response to the evolving needs of the global health market. This transition marks not just a change in leadership but a comprehensive strategy to enhance Suanfarma’s legacy in the industry.